| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
| Calendar year (or fiscal year beginning in) | (a) 2021 | (b) 2022 | (c) 2023 | (d) 2024 | (e) 2025 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 3,616,583 | 2,557,425 | 2,676,417 | 4,042,875 | 5,045,092 | 17,938,392 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 3,616,583 | 2,557,425 | 2,676,417 | 4,042,875 | 5,045,092 | 17,938,392 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 5,760,999 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 12,177,393 | |||||
| Calendar year (or fiscal year beginning in) | (a) 2021 | (b) 2022 | (c) 2023 | (d) 2024 | (e) 2025 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 3,616,583 | 2,557,425 | 2,676,417 | 4,042,875 | 5,045,092 | 17,938,392 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 98,435 | 325,797 | 386,991 | 355,404 | 390,113 | 1,556,740 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 60,000 | 30,000 | 90,000 | |||
| 11 | Total support. Add lines 7 through 10 | 19,585,132 | |||||
| Calendar year (or fiscal year beginning in) | (a) 2021 | (b) 2022 | (c) 2023 | (d) 2024 | (e) 2025 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2021 | (b) 2022 | (c) 2023 | (d) 2024 | (e) 2025 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6 | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975 | ||||||
| c | Add lines 10a and 10b | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6Total annual distributions. Add lines 1 through 5. | 6 | |
|
7
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
7 | |
| 8 Distributable amount for 2025 from Section C, line 6 | 8 | |
| 9 Line 7 amount divided by Line 8 amount | 9 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2025 |
(iii) Distributable Amount for 2025 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2025 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2025 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2025: | ||||
| a From 2020....... | ||||
| b From 2021....... | ||||
| c From 2022....... | ||||
| d From 2023....... | ||||
| e From 2024....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2025 distributable amount | ||||
|
i
Carryover from 2020 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2025 from Section D, line 6: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2025 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2025, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2025. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2026. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2021..... | ||||
| b Excess from 2022..... | ||||
| c Excess from 2023..... | ||||
| d Excess from 2024..... | ||||
| e Excess from 2025..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| PART II, LINE 10 | 90,000 |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990 - ORGANIZATION'S MISSION | THE GLAUCOMA FOUNDATION, INC. IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA, THE LEADING CAUSE OF PREVENTABLE BLINDNESS. THE STRATEGY TO ACHIEVE THIS GOAL IS TWO-FOLD: RAISE PUBLIC AWARENESS CONCERNING THE NECESSITY OF ROUTINE EYE EXAMS, AND FUND CRITICAL RESEARCH TO FIND CURES FOR GLAUCOMA. |
| FORM 990, PAGE 2, PART III, LINE 4A | 1) MULTIPLE WEBINARS: WHAT DO COLD HANDS HAVE TO DO WITH GLAUCOMA? THE PROMISE OF OPTIC NERVE REGENERATION; THE BODY-EYE RELATIONSHIP HOW TO SAVE THE SIGHT OF PATIENTS WITH GLAUCOMA WHILE MINIMIZING ADVERSE REACTION FROM EYE DROPS; INSIGHTS INTO GLAUCOMA & WOMEN'S HEALTH: EXPLORING THE IMPACT OF MENOPAUSE AND VISUAL FUNCTION; GLAUCOMA AND LIFESTYLE. 2) THE OPTIC NERVE RESCUE AND RESTORATION THINK TANK "A PATIENT-CENTRIC APPROACH WHILE INCORPORATING THE LATEST SCIENCE" GLAUCOMA DATA INTEGRATION: OVERVIEW OF DATABASES AVAILABLE TO ADVANCE GLAUCOMA KNOWLEDGE; LESSONS LEARNED ABOUT GLAUCOMA FROM THE UK BIOBANK; POAG GENOMIC ARCHITECTURE; A 360-DEGREE BIOMEDICAL PROFILE OF HEALTH: LESSONS FROM CARDIOVASCULAR DISEASE. 3) DRUG RE-PURPOSING IN GLAUCOMA: INSULIN SIGNALING AND; METFORMIN AND GLAUCOMA; GLP-1R AGONISTS AND GLAUCOMA. 4) OVERVIEW OF GLAUCOMA NEUROPROTECTION AGENTS: WHY DO WE NOT HAVE A NEUROPROTECTION AGENT FOR GLAUCOMA? HOW CAN AI HELP FACILITATE RANDOMIZED CLINICAL TRIALS IN NEUROPROTECTION? 5) SEX HORMONES AND GLAUCOMA: THE ROLE OF SEX HORMONES IN THE PATHOGENESIS OF OPEN-ANGLE GLAUCOMA: EVIDENCE FROM EPIDEMIOLOGICAL STUDIES; ESTROGEN SIGNALING PATHWAYS IN GLAUCOMA; THE BIOMECHANICAL ARGUMENT THAT ESTROGEN PLAYS A ROLE IN GLAUCOMA; 6) NON-IOP FACTORS OF IMPORTANCE IN GLAUCOMA: DIET AND GLAUCOMA; HYPERTENSION, ANTIHYPERTENSIVE DRUGS AND GLAUCOMA; THE IMPACT OF GLAUCOMA ON ACTIVITIES OF DAILY LIVING. 7) WHAT CAN TGF DO TO HELP PATIENTS, RESEARCHERS, AND EYECARE PROVIDERS TACKLE GLAUCOMA?: WHAT IS THE GLAUCOMA FOUNDATION DOING NOW? WHAT DO PATIENTS WANT TO SEE IN GLAUCOMA RESEARCH? 8) START WITH THE YOUNG: INFO SESSION ON GLAUCOMA FOR MIDDLE AND HIGH SCHOOL STUDENTS; IN COORDINATION WITH THE STEM INSTITUTE AT THE CITY COLLEGE OF NEW YORK. 9) NEWSLETTERS: TGF PRODUCED SIX ELECTRONIC NEWSLETTERS THAT WERE DISTRIBUTED TO MORE THAN 16,000 HOUSEHOLDS. TGF'S QUARTERLY PRINTED NEWSLETTERS WERE AVAILABLE FOR CONSTITUENTS WHO DO NOT USE COMPUTERS OR WHO PREFER TO READ PAPER DOCUMENTS. NEWSLETTERS INCLUDE INTERVIEWS WITH DOCTORS, RESEARCHERS, AND PATIENTS. THEY COVER TOPICS SUCH AS ADVANCEMENTS IN DIAGNOSIS AND TREATMENT, PERSPECTIVES ON CARE, AND PERSONAL STORIES OF LIVING WITH THE DISEASE. |
| FORM 990, PAGE 2, PART III, LINE 4B | 1) GENETIC PREDISPOSITION AND OPHTHALMIC OUTCOMES; 2) OPTIC NERVE REGENERATION; 3) USING ARTIFICIAL INTELLIGENCE TO REVEAL BLOOD PRESSURE'S ROLE IN GLAUCOMA PROGRESSION; 4) EE-PURPOSING AN "OLD" DRUG FOR A NEW INDICATION: ELUCIDATING THE PERIPHERAL AND CENTRAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS TO TREAT GLAUCOMA; 5) SEARCH FOR FUNCTIONAL LOXL1 RISK ALLELES WITH BIT-STARR; 6) VASCULAR GENOTYPE-PHENOTYPE ASSOCIATION IN PRIMARY OPEN-ANGLE GLAUCOMA; 7) INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA; 8) UNCOVERING THE POTENTIAL OF PERICYTES AS THERAPEUTIC TARGETS FOR GLAUCOMA; 9) NICOTINAMIDE AND PYRUVATE FOR NEUROENHANCEMENT IN OPEN-ANGLE GLAUCOMA: A PHASE 2 RANDOMIZED CLINICAL TRIAL. |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE CHIEF EXECUTIVE OFFICER AND THE ASSISTANT TREASURER REVIEW FORM 990 IN DETAIL AND THEN MAKE IT AVAILABLE TO THE GOVERNING BOARD PRIOR TO BEING FILED. |
| FORM 990, PAGE 6, PART VI, LINE 12C | THE ORGANIZATION HAS A BOARD APPROVED CONFLICT OF INTEREST POLICY. EACH BOARD MEMBER MUST FILL OUT AN ANNUAL DECLARATION STATING THEY HAD NO CONFLICTS OR IDENTIFYING THE NATURE OF THEIR INTERESTED PARTY TRANSACTIONS. |
| FORM 990, PAGE 6, PART VI, LINE 15A | EACH YEAR, THE COMPENSATION COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE PRESIDENT/CEO TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS. |
| FORM 990, PAGE 6, PART VI, LINE 15B | EACH YEAR, THE COMPENSATION COMMITTEE REVIEWS COMPARABLE SALARIES BASED ON A RECOGNIZED STUDY AND REVIEWS THE PERFORMANCE OF THE PRESIDENT/CEO TO DETERMINE IF THE EXISTING SALARY FALLS WITHIN THESE RANGES. AFTER A DELIBERATION OF THIS MATTER, A NEW PROPOSED SALARY AND BENEFIT PACKAGE IS VOTED ON. THE MINUTES OF THE BOARD OF DIRECTORS REFLECT THE NATURE OF THIS PROCESS. |
| FORM 990, PAGE 6, PART VI, LINE 17 | MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE ORGANIZATION MAKES ITS PUBLIC DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO PUBLIC. |
| Software ID: | |
| Software Version: |